Targeting the Transforming Growth Factor-β Signaling in Cancer Therapy
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
TGF-β pathway is being extensively evaluated as a potential therapeutic target. The transforming growth factor-β (TGF-β) signaling pathway has the dual role in both tumor suppression and tumor promotion. To design cancer therapeutics successfully, it is important to understand TGF-β related functional contexts. This review discusses the molecular mechanism of the TGF-β pathway and describes the different ways of tumor suppression and promotion by TGF-β. In the last part of the review, the data on targeting TGF-β pathway for cancer treatment is assessed. The TGF-β inhibitors in pre-clinical studies, and Phase I and II clinical trials are updated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Massagué, J. (2008) · Cell · doi:10.1016/j.cell.2008.07.001 · Cited by 3,907 · cited 1×
“In most epithelial, endothelial and hematopoietic cells, TGF-β arrest cell cycle at G1 by inducing or activating cdk inhibitors such as, p16INK4A, p15INK4B, p21CIP1 and/or p27Kip1 (Massagué and Gomis, 2006).”
TGF-β Signaling in Tumor Suppression and Cancer Progression
Derynck, R., Akhurst, R. J., & Balmain, A. (2001) · Nature Genetics · doi:10.1038/ng1001-117 · Cited by 2,275 · cited 1×
“TGF-β increases angiogenesis, activities of metalloproteases MMP-2 and MMP9, and inhibits protease inhibitor TIMP (Derynck et al., 2001; Hagedorn et al., 2001; Sánchez-Elsner et al., 2001; Kang et al., 2003; Padua and Massagué, 2009).”
BackgroundTGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance
Thomas, D. A., & Massagué, J. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.012 · Cited by 1,355
Three-dimensional culture models of normal and malignant breast epithelial cells
Lee, G. Y., Kenny, P. A., Lee, E. H., & Bissell, M. J. (2007) · Nature Methods · doi:10.1038/nmeth1015 · Cited by 1,336 · cited 2×
“Mutations of TβRII and TβRI are relatively rare in breast, skin and hematological cancers (Dong and Blobe, 2006; Levy and Hill, 2006; Connolly et al., 2012).”
The polarization of immune cells in the tumour environment by TGFβ
Flavell, R. A., Sanjabi, S., Wrzesinski, S. H., & Licona-Limón, P. (2010) · Nature Reviews Immunology · doi:10.1038/nri2808 · Cited by 940 · cited 1×
“2G7, another mAB in pre-clinical trials, showed effi cacy in inhibiting breast cancer metastasis by increasing NK cells activity (Arteaga et al., 1993; Biswas et al., 2007; Ganapathy et al., 2010).”
Alterations in components of the TGF-β superfamily signaling pathways in human cancer
LEVY, L., & HILL, C. (2006) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.09.009 · Cited by 539 · cited 1×
“Smads act as transcriptional regulatory factors of EMT regulators such as Snail/Slug/Twist, Cripto-1 and Six1 (Thuault et al., 2006; Micalizzi et al., 2009; ViloriaPetit et al., 2009; Lindley and Briegel, 2010; Micalizzi et al., 2010; Wendt et al., 2010; Shirakihara et al., 2011).”
Yang, Y.-A., Dukhanina, O., Tang, B., Mamura, M., Letterio, J. J., MacGregor, J., Patel, S. C., Khozin, S., Liu, Z.-Y., Green, J., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci200215333 · Cited by 404
Subramanian, G., Schwarz, R. E., Higgins, L., McEnroe, G., Chakravarty, S., Dugar, S., & Reiss, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0018 · Cited by 138
Connolly, E. C., Saunier, E. F., Quigley, D., Luu, M. T., De Sapio, A., Hann, B., Yingling, J. M., & Akhurst, R. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2941 · Cited by 82
Cited by
Oncogenic Signaling Pathways in The Cancer Genome Atlas
Sanchez-Vega, F., Mina, M., Armenia, J., Chatila, W. K., Luna, A., La, K. C., Dimitriadoy, S., Liu, D. L., Kantheti, H. S., Saghafinia, S., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.035 · Cited by 3,201
“…to develop therapies that target additional pathways, some of which are in clinical trials (Table S6) (Park and Guan, 2013), (Whitfield et al., 2017), (Whitfield et al., 2017), (Aster and Blacklow, 2012), (Takebe et al., 2014), (Buijs et al., 2012), (Sheen et al., 2013), (Pai et al., 2017).”
BackgroundImmunomodulation‐Enhanced Nanozyme‐Based Tumor Catalytic Therapy
Xu, B., Cui, Y., Wang, W., Li, S., Lyu, C., Wang, S., Bao, W., Wang, H., Qin, M., Liu, Z., et al. (2020) · Advanced Materials · doi:10.1002/adma.202003563 · Cited by 404
Jung, S. Y., Hwang, S., Clarke, J. M., Bauer, T. M., Keedy, V. L., Lee, H., Park, N., Kim, S.-J., & Lee, J. I. (2020) · Investigational New Drugs · doi:10.1007/s10637-019-00835-y · Cited by 69
Mehdipour, M., Etienne, J., Chen, C.-C., Gathwala, R., Rehman, M., Kato, C., Liu, C., Liu, Y., Zuo, Y., Conboy, M. J., et al. (2019) · Aging · doi:10.18632/aging.102148 · Cited by 39
Metadata
- Authors
- Sheen, Y. Y., Kim, M.-J., Park, S.-A., Park, S.-Y., & Nam, J.-S.
- Venue
- Biomolecules and Therapeutics
- Published
- 2013-09-30
- Volume
- 21
- Issue
- 5
- Pages
- 323-331
- ISSN
- 1976-9148 (ISSN-L)
- OpenAlex
- W2076365499
- Cited by
- 105
- References
- 9
- FWCI
- 3.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting the Transforming Growth Factor-β Signaling in Cancer Therapy. https://app.cochat.ai/papers/10.4062/biomolther.2013.072
- The paper
- Sheen, Y. Y., Kim, M.-J., Park, S.-A., Park, S.-Y., & Nam, J.-S. (2013). Targeting the Transforming Growth Factor-β Signaling in Cancer Therapy. Biomolecules and Therapeutics. https://doi.org/10.4062/biomolther.2013.072
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.